Navigation Links
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
Date:3/26/2013

ts show that OMS824, at well-tolerated doses, achieves concentrations that are anticipated to effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.

"These results are exciting – it appears that OMS824 is able to achieve significantly higher concentrations at the target enzyme in the brain than other PDE10 inhibitors being developed across the industry without incurring the movement abnormalities seen with those other compounds," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "While wrapping up the Phase 1 program, we are aggressively advancing OMS824 into Phase 2 trials. Our initial focus will be Huntington's disease, for which we will be requesting orphan drug as well as Fast Track designations from the FDA, and a Phase 2a trial in patients with schizophrenia is expected to follow shortly thereafter. In addition to our progress in the OMS824 program, we plan to submit the NDA next quarter and the MAA mid-year for OMS302, our ophthalmic drug product, and we remain on track to advance our MASP-2 and PDE7 programs into the clinic in the coming months."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Cognitive dysfunction is responsible for substantial disability in these diseases and is not improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve psychiatric manifestations, such as the positive (e.g., halluci
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
2. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
4. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
5. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
6. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
7. Omeros is Not Aware of Any Justification for Share Price Movement
8. Omeros Corporation Reports Third Quarter 2012 Financial Results
9. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
10. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
(Date:8/22/2014)... -- Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... its President and Chief Executive Officer, will be stepping ... a member of the Board of Directors, effective as ... an interim basis by Michael T. Leatherman , ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... 2012   OphthaliX (OTCBB: OPLI) today reported its ... 31, 2012. OphthaliX is an advanced clinical-stage biopharmaceutical company ... ophthalmic disorders.  Our drug, CF101 (known generically as IB-MECA), ... eye syndrome; glaucoma and uveitis. We are currently: (i) ...
...  Fluke Biomedical announced today the newest addition to ... and troubleshooting tools, the SPOT Light SpO2 ... maintenance (PM) test for SpO2 patient monitor functionality, ... SpO2 functional tester ever achieved by this industry-leading ...
Cached Medicine Technology:OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester 2
(Date:8/22/2014)... MyWriters.com , an online source ... experts for marketers to help them drive traffic to ... of Shane Michaels, prompting an investigative review. , ... way knows that content is king when it comes ... “But even though content is extremely important, creating quality, ...
(Date:8/22/2014)... Boston, Mass. (PRWEB) August 22, 2014 ... Chain Drug Stores (NACDS) Total Store Expo - which ... Boston Globe published a pro-pharmacy op-ed in its online ... medical care, enlist pharmacists ” is co-authored by Steven ... and Michael Malloy, PharmD, dean of the MCPHS University ...
(Date:8/22/2014)... Indiana (PRWEB) August 22, 2014 The ... Toyota Indiana is on the grow again. ... 300 jobs by summer 2016 to boost production of ... will bring Toyota Indiana’s overall investment to $4 billion. ... North America while providing additional flexibility to adjust its ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
Breaking Medicine News(10 mins):Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... 8 (HealthDay News) -- The brains of new taxi drivers ... places of interest over several years, a new study shows. ... to changes in the adult brain, which is good news ... according to the U.K. researchers. The study included people ...
... , THURSDAY, Dec. 8 (HealthDay News) -- Some ... cancer genes from their father may be diagnosed with breast ... genes from their mother, a new study indicates. Researchers ... patients with the BRCA1 or BRCA2 mutations to determine the ...
... Nurses working in hospitals around the world are reporting they ... at the University of Pennsylvania School of Nursing,s Center for ... nurses in nine countries. Between 20 to 60 ... study, published in the International Journal for Quality in ...
... study of South American songbirds completed by the Department ... of Natural History, has discovered these birds differ dramatically ... differences which indicates they are on the road to ... to show that species could change, that they were ...
... of Copenhagen have explored the active principles of a Danish ... are particularly toxic towards cancer cells. The goal is to ... useful in future drug development. Asia has a ... natural products. Many substances found in fungi are today registered ...
... health care system in the United States faces numerous challenges: ... how to ensure more equitable use of medical services and, ... for that care. The 10th Biennial Regenstrief Institute ... Medical Care tackles key conceptual questions, reviews effective ...
Cached Medicine News:Health News:Taxi Drivers Show How Learning Changes Adult Brain 2Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2Health News:To keep nurses, improve their work environments 2Health News:Danish mushroom inspires cancer researchers 2Health News:Danish mushroom inspires cancer researchers 3Health News:Journal supplement presents strategies for introducing health care delivery innovation 2
... replace the carpal scaphoid bone. The implant has ... under a shelf formed in the carpal trapezium ... the proximal hole for suture fixation. These temporarily ... period until a firm capsuloligamentous system has formed ...
... has the same anatomical configuration as the ... to provide for stability. The implant has ... use in suture fixation through the scaphoid ... while a capsuloligamentous system forms around the ...
... for four corner fusion of the capitate, ... hand. The plate is intended for use ... of function due to SLAC and SNAC ... rheumatoid arthritis. When combined with the specially ...
The 3.0 mm Cannulated Screw can be used with or without threaded washer. Uses 1.1 mm threaded or non-threaded guide wire. , ,The Threaded Washer provides a recessed internal buttress which allows the...
Medicine Products: